Kymab submits confidential draft registration statement for proposed initial public offering in the United States

Cambridge, UK May 13, 2019: Kymab Group Limited today announced that it has previously confidentially submitted a draft registration statement on Form F-1 to the US Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of American Depositary Shares, each of which will represent one or a number of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (“Securities Act”). This announcement is being issued in accordance with Rule 135 under the Securities Act.

###ENDS###

Notes to Editors

About Kymab

Kymab a clinical-stage biopharmaceutical company developing a deep pipeline of novel antibody-based therapies focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary technology platforms collectively called IntelliSelect. Kymab’s platforms have been designed to maximize the diversity of human antibodies produced in response to immunization with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.

About IntelliSelect

The IntelliSelect Transgenic platforms are designed to generate best-in-class, fully-human monoclonal antibodies from several highly-engineered strains of mice that have the complete constellation of human antibody building blocks in their genome.

The IntelliSelect Screening technology combines single cell sequencing, genomics and proprietary bioinformatic algorithms to prioritize and select antibodies generated by the IntelliSelect Transgenic platforms that have the most desirable drug-like properties.

For more information please see http://www.kymab.com. Kymab and IntelliSelect are trademarks of Kymab Limited.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include
statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

**For further information contact:**

**US**  
Katie Engleman, 1AB  
katie@1abmedia.com

**Europe**  
Consilium Strategic Communications:  
Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji / Melissa Gardiner  
+44 (0) 20 3709 5700  
kymab@consilium-comms.com

**Investors**  
Brandon Lewis, +44 (0)1223 833301  
brandon.lewis@kymab.com